Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Te

Patent Covers Acclaim-3 Clinical Trials Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecent

The BIO International Convention Brings Together More Than 20,000 Biotech Industry Leaders From Arou

https://www.sec.gov/Archives/edgar/data/1595248/000143774926019760/gnpx20260518_s3.htm

Trop-2 H-scores Above 100 and PTEN H-scores Below 100 Correlated With Longer Progression Free Surviv

Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GNPX), a clinical-stage gene the

Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Te

Genprex (NASDAQ:GNPX) reported quarterly losses of $(0.64) per share. This is a 95.08 percent increa

The health care sector has oversold stocks with RSI below 30, presenting an opportunity for traders

Strengthens Patent Estate and Expands Protection in Another Target MarketAUSTIN, Texas, April 30, 20

Strengthens Patent Estate and Expands Protection in Another Target Market AUSTIN, Texas, April 30, 2

Pdx1/MafA Gene Therapy Reversed Hyperglycemia in Type 2 Diabetic Models Within Four Weeks AUSTIN, Te

AUSTIN, Texas, April 22, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GN

Research on Biomarkers May Help Enrich Acclaim-1 and Acclaim-3 Lung Cancer Clinical Trials, Potentia

TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene TherapyREQORSA Induced Apopt

TROP2 and PTEN Biomarkers May Predict Patient Response to Reqorsa® Gene Therapy REQORSA Induced Apop

Genprex (NASDAQ: GNPX - Get Free Report) and Cullinan Therapeutics (NASDAQ: CGEM - Get Free Report)

A Congress member continues to buy small cap stocks. Here's the latest names added to his invest

Genprex (NASDAQ: GNPX - Get Free Report) will likely be issuing its resultson Friday, March 27th. An

Research Collaborators Identify Biomarkers that May Predict Patient Response to Reqorsa® Gene Therap

AUSTIN, Texas, March 10, 2026 /PRNewswire/ -- Genprex, Inc. ("Genprex" or the "Company") (NASDAQ: GN

Japanese Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'

Patent Covers Acclaim-3 Clinical Trial Combining REQORSA Gene Therapy with Genentech, Inc.'s Tecentr

A Republican U.S. Representative made multiple trades in 2025, including Cracker Barrel and a little

Company Achieves Clinical Development Milestones in 2025, Advances Program for Future Scale Up and S

Preliminary Preclinical Data Demonstrates In Vivo Proof-of-Concept for Novel Diabetes Gene Therapy i

The list of the top 10 members of Congress for 2025 investment portfolio gains. Where did Marjorie T

Genprex (NASDAQ: GNPX - Get Free Report)'s stock price dropped 3.8% during mid-day trading on Friday

  During the session on Thursday, 461 stocks hit new 52-week lows.

Stocks Which Set New 52-Week Low Yesterday, Tues., Nov. 20, 2018

Stocks Which Set New 52-Week Low Friday, October 26th

Stocks Which Set New 52-Week Low Yesterday, October 23rd

Stocks Which Set New 52-Week Low Yesterday, October 11th

Stocks Which Set New 52-Week Low Yesterday, October 10th

Stocks Which Set New 52-Week Low Yesterday, October 9th

Stocks Which Set New 52-Week Low Friday, October 5th